Dr. Li Describes the Future of Lung Cancer Therapy

Tianhong Li, MD, PhD
Published: Monday, Sep 19, 2011

Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, believes the future of lung cancer will involve a shift towards personalized care.

There is quite a lot of heterogeneity in lung tumors making the detection of mutations, such as ALK for the use of crizotinib (Xalkori), more important. This type of genetic testing should become more heavily used to determine future treatments.

Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, believes the future of lung cancer will involve a shift towards personalized care.

There is quite a lot of heterogeneity in lung tumors making the detection of mutations, such as ALK for the use of crizotinib (Xalkori), more important. This type of genetic testing should become more heavily used to determine future treatments.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x